Sun Pharma’s earnings pace is likely to slow down as it takes two steps back for a leap forward

A bird flies past the logo of Sun Pharma installed on the facade of its corporate office in Mumbai, India.


Dilip Shanghvi’s Sun Pharma made a bold move entering the specialty-drugs business which has started to pay it back. Now, the company is scouting acquisitions and augmenting its in-house R&D to enhance its specialty-drugs pipeline. This investment phase may come at the expense of profitability, but for how long?

Dilip Shanghvi has silenced the sceptics. People were unsure about what Shanghvi, founder and managing director of India’s largest pharmaceutical company, Sun Pharmaceutical Industries (Sun Pharma), was up to with his company’s foray in 2013 into the specialty-drugs business. Many questioned the company’s ability to crack the business. But despite the brickbats, the company invested at least USD1.6 billion in the specialty-drugs business over

  • SAVE

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

  • ​Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-​

Leave a Reply

Your email address will not be published. Required fields are marked *